الفهرس 
Diabetes mellitusOnly 14 pages are availabe for public view
 |  | from | 207 |  |  |
| | | from | 207 | | |
Abstract
Patients with type 2 diabetes mellitus (T2DM)present with an accelerated tendency for developing atherosclerotic cardiovascular disease(ASCVD).There is a global trend for assessing the cardiovascular(CV)effect and safety of the antihyperglycemic agents, yet clinical data regarding the CV effect of vildagliptin are scarcely available.This study aimed to assess the CV effect of vildagliptin therapy through evaluating its effect on biological markers of inflammation, pro-thrombogenicity, and other devastating CV risk parameters in patients with T2DM